Namrata Saroj, Chief Business Officer of Ocular Therapeutix, Inc., filed a Form 4 on November 9, 2026, disclosing the sale of 35,370 shares of common stock on November 5, 2026, pursuant to a Rule 10b5-1 automatic sale instruction to cover tax withholding obligations tied …
Franklin Financial Services Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing third-quarter net income of $8,535 thousand and nine-month net income of $21,783 thousand.
Artiva Biotherapeutics, Inc. filed a Form 8-K/A amendment on November 9, 2026, providing cost estimates for its previously announced wind-down of AlloNK development and workforce reduction that were unavailable at the time of the original October 27, 2026 filing.
American Public Education, Inc. filed a Form 8-K with the SEC on November 9, 2026, reporting that it issued a press release covering financial results for the three and nine months ended September 30, 2026.
Inogen, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the three and nine months ended September 30, 2026, disclosing a net loss of $16.2 million for the quarter and a $10.6 million impairment charge recorded in …
Werner Enterprises, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting a return to profitability in the third quarter after a loss in the same period a year earlier.
Thryv Holdings, Inc. (NASDAQ:THRY) submitted its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a going-concern warning and ongoing strategic initiatives including a planned divestiture of its print business.
WhiteHawk Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting continued operating losses and balance sheet changes following a mid-year private placement.
The Hain Celestial Group, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting net sales of $260,274 thousand and an operating loss of $14,976 thousand for the three …
National Health Investors, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 9, 2026, reporting results for the three and nine months ended that date.